Posts Tagged ‘ Garrard ’

Lead Counsel Chosen in Transvaginal Mesh Cases

Apr 13th, 2012 | By
Lead Counsel Chosen in Transvaginal Mesh Cases

Friday, April 13, 2012 ~ This morning the lead attorneys were chosen who will represent the transvaginal surgical mesh product liability cases consolidated in the Southern District of West Virginia and the Honorable Judge Joseph Goodwin. Bryan F. Aylstock (Aylstock, Witkin, Kreis, and Overholtz),  Henry Garrard (Blasingame, Burch, Garrard, Ashley)  and Fred Thompson (Motley Rice)
[continue reading...]



Lead Attorneys to be Chosen in Transvaginal Mesh Cases Friday, April 13

Apr 12th, 2012 | By
Lead Attorneys to be Chosen in Transvaginal Mesh Cases Friday, April 13

The Honorable Judge Joseph Goodwin will oversee a hearing Friday, April 13, to decide who will be the lead attorneys in the consolidated lawsuits over defective transvaginal mesh. Hundreds of cases have been consolidated in the Southern District of West Virginia in Multidistrict litigation (MDL) that name mesh manufacturers Ethicon, Inc ( MDL No. 2327),
[continue reading...]



Plaintiffs Want Mesh Lawsuits Centralized

Dec 22nd, 2011 | By
Plaintiffs Want Mesh Lawsuits Centralized

DECEMBER 22, 2011 – The Athens Georgia law firm of Blasingame, Burch, Garrard & Ashley, P.C. has filed a motion to have various plaintiffs from around the country centralize their defective transvaginal surgical mesh litigation in one federal court – the Southern District of West Virginia. Share this:



We hope you find this a helpful resource. National News Editor, Jane Akre, began MDND with the hope of providing the latest news, information and perspective from the regulatory, industry and patient point of view, something that goes under-reported in much of the coverage of medical devices. The public is just now becoming aware that many devices do not undergo the same scrutiny as prescription drugs and are instead grandfathered in under an FDA loophole that has gone largely unchanged since the 1970s. As a result, patients become the post-market clinical trial subjects, and many suffer devastating and permanent injuries.